Abstract: Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed herein.
Type:
Application
Filed:
June 24, 2011
Publication date:
August 22, 2013
Applicant:
Ironwood Pharmaceuticals, Inc.
Inventors:
Takashi Nakai, James Jia, Jason Rohde, Regina Graul, Ara Mermerian
Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.
Type:
Grant
Filed:
November 9, 2010
Date of Patent:
August 13, 2013
Assignee:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel P. Zimmer
Abstract: The present disclosure relates to compounds useful as agonists of cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders either alone or in combination therapy.
Type:
Application
Filed:
February 9, 2011
Publication date:
August 1, 2013
Applicant:
Ironwood Pharmaceuticals, Inc.
Inventors:
Jason Rohde, Charles Kim, Takashi Nakai, Galen John Carey
Abstract: The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.
Type:
Application
Filed:
March 15, 2013
Publication date:
July 25, 2013
Applicants:
Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
Abstract: The present disclosure relates to compounds useful as agonists of the cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders, either alone or in combination therapy. The compounds of the invention have Formula (I).
Type:
Application
Filed:
February 9, 2011
Publication date:
July 11, 2013
Applicant:
Ironwood Pharmaceuticals, Inc.
Inventors:
Jason Rohde, Bo Peng, Takashi Nakai, Kevin Sprott, Ara Mermerían, Wayne C. Schairer, Galen John Carey
Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
Type:
Application
Filed:
March 10, 2011
Publication date:
July 11, 2013
Applicant:
IRONWOOD PHARMACEUTICALS, INC.
Inventors:
Joel Moore, James Jia, Takashi Nakai, Charles Kim, Thomas Wai-Ho Lee, Jane Yang
Abstract: Disclosed herein are novel compositions and methods for treating or preventing metabolic syndromes. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a combination of at least one antidiabetic agent, at least one proton pump inhibitor and at least one bile acid sequestrant, and, optionally, at least one active agent, including, but not limited to, dyslipidemia agents, histamine H2 receptor blockers, antacids, ?-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, protease inhibitors and combinations of two or more thereof.
Abstract: The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors to treat aspects of Parkinson's disease (PD), restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), the use of FAAH inhibitors for the manufacture of medicaments for use in the treatment of PD, RLS and PLMD, as well as pharmaceutically acceptable compositions comprising FAAH inhibitors for use in the treatment of PD, RLS and PLMD.
Type:
Application
Filed:
January 7, 2011
Publication date:
June 13, 2013
Applicants:
Ironwood Pharmaceutical, Inc.
Inventors:
James Philip Pearson, Todd G. Milne, Thomas Henry Johnston, Jonathan Michael Brotchie
Abstract: Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.
Type:
Application
Filed:
December 7, 2010
Publication date:
May 23, 2013
Applicant:
IRONWOOD PHARMACEUTICALS, INC
Inventors:
Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian Cali
Abstract: Disclosed herein are novel compositions and methods for treating or preventing GI tract disorders and/or GERD-related respiratory disorders as well as protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.
Abstract: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more sGC modulators alone or in combination with one or more lipid altering agents and/or PDE inhibitors.
Abstract: The present disclosure relates to N-benzyl pyrrole compounds of formula (I) useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders.
Type:
Application
Filed:
December 8, 2010
Publication date:
May 2, 2013
Applicant:
Ironwood Pharmaceuticals, Inc.
Inventors:
Kevin Sprott, John Jeffrey Talley, Jane Yang, Bo Peng
Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.
Type:
Application
Filed:
November 9, 2010
Publication date:
April 4, 2013
Applicant:
IRONWOOD PHARMACEUTICALS, INC
Inventors:
Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel P. Zimmer
Abstract: The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide.
Abstract: A method of modulating the pharmacodynamic effect of a GC-C receptor agonist polypeptide formulation in a subject in need of such treatment is disclosed, The method comprises administering the GC-C receptor agonist polypeptide formulation to the subject before the ingestion of food.
Abstract: The present disclosure relates to compounds of formula I useful as agonists of cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders.
Type:
Application
Filed:
July 9, 2010
Publication date:
January 31, 2013
Applicant:
IRONWOOD PHARMACEUTICALS, INC
Inventors:
Kevin Sprott, Jason Rohde, Takashi Nakai, Bo Peng, John Jeffrey Talley
Abstract: The present invention relates to orally disintegrating or dissolving pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well to various methods and processes for the preparation and use of the compositions.
Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders and disorders and conditions associated with excess fluid and/or salt retention as well as other conditions and disorders are described. The compositions feature polypeptides that activate the guanylate cyclase C (GC-C) receptor.
Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
Type:
Application
Filed:
August 14, 2009
Publication date:
August 23, 2012
Applicants:
Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
Inventors:
Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
Type:
Application
Filed:
March 22, 2012
Publication date:
August 2, 2012
Applicant:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Shalina Mahajan-Miklos, Li Jing Sun